You have 9 free searches left this month | to do more
Showing 1 - 25 of
2,888 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
2022-02-22
Feb 22, 2022
M
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Recruiting
  • MDS
  • AML
  • Bronx, New York
    Montefiore Medical Center
2022-03-24
Mar 24, 2022
Z
NK Cell Therapy for AML
Active, not recruiting
  • AML
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
2022-02-21
Feb 21, 2022
U
Decitabine and Talazoparib in Untreated AML and R/R AML
Active, not recruiting
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
2021-10-05
Oct 5, 2021
M
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) - 2021
Terminated
Has Results
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
2021-09-29
Sep 29, 2021
H
Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
Recruiting
  • AML
  • Hyperleukocytosis
  • Monterrey, Nuevo Leon, Mexico
    Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitari
2021-10-09
Oct 9, 2021
C
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Not yet recruiting
  • AML
  • Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
  • (no location specified)
2022-01-05
Jan 5, 2022
H
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib - 2022
Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022
A
Venetoclax and Lintuzumab-Ac225 in AML Patients
Recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • Los Angeles, California
  • +4 more
2022-02-22
Feb 22, 2022
M
Diagnosis and Treatment of Periodontal Disease in Patients With AML
Not yet recruiting
  • AML
  • Acute Myelogenous Leukemia
  • Scaling and Root Planing
  • (no location specified)
2021-08-03
Aug 3, 2021
M
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
Not yet recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
C
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
Not yet recruiting
  • Myeloid Leukemia
  • Interviews
  • (no location specified)
2022-03-25
Mar 25, 2022
B
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Recruiting
  • Acute Myeloid Leukemia
  • NK cell infusions
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
2022-02-28
Feb 28, 2022
U
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
Recruiting
  • AML, Adult
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
2022-01-27
Jan 27, 2022
U
Cardioprotection in AML
Recruiting
  • AML
  • Acute Myeloid Leukemia
  • Charlottesville, Virginia
    University of Virginia
2022-03-09
Mar 9, 2022
C
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Not yet recruiting
  • Acute Myeloid Leukemia in Remission
  • Prospective determination of the clinical utility of measurable residual disease (MRD) testing
  • (no location specified)
2022-01-25
Jan 25, 2022
A
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Withdrawn
  • AML
  • APVO436
  • (no location specified)
2021-11-29
Nov 29, 2021
H
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Recruiting
  • Myeloid Malignancy
  • Detroit, Michigan
    Henry ford hospital
2021-12-23
Dec 23, 2021
B
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Active, not recruiting
  • Acute Myelogenous Leukemia
  • AML
  • DC AML Vaccine
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
2022-01-25
Jan 25, 2022
S
Phase 1 Study of Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • San Francisco, California
    Stanford University
2022-02-07
Feb 7, 2022
W
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Recruiting
  • Whole Genome Sequencing
  • +2 more
  • ChromoSeq
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-04-06
Apr 6, 2022
H
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation
Recruiting
  • AML
  • CAR-γδT
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
2021-03-11
Mar 11, 2021
W
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
2022-02-23
Feb 23, 2022
D
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Recruiting
  • Acute Myelogenous Leukemia
  • Boston, Massachusetts
  • +1 more
2021-11-15
Nov 15, 2021
H
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Recruiting
  • Myelodysplastic Syndromes
  • Secondary Acute Myeloid Leukemia
  • CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
  • Standard of Care Chemotherapy
  • Tampa, Florida
    Moffitt Cancer Center
2022-01-26
Jan 26, 2022